Issue link: http://clhia.uberflip.com/i/406567
38 16. The CLHIA recommends that: • Health Canada develop a policy and practice with respect to designating SEBs as bio-equivalent (and hence interchangeable) and that this be informed by the work underway in other jurisdictions; and • The Council of the Federation's Health Care Innovation Working Group develop national clinical guidelines for what will constitute safe switching from biologics to SEBs that are grounded in the best available medical evidence. C. IMPROVING REIMBURSEMENT MODELS 17. The CLHIA recommends that provincial governments commit as a priority, to work with private payers to develop transparent and efficient operational processes to facilitate the seamless transition of patients between public and private coverage. 18. The CLHIA recommends that governments, in collaboration with the private sector, work towards the development of a common, national minimum formulary. 19. The CLHIA recommends that from a policy perspective that it would be in the interest of governments and private insurers to enter into a dialogue to develop a national, comprehensive, high cost drug strategy in order to ensure the sustainability of drug coverage going forward. D. IMPROVING COLLABORATION WITH KEY STAKEHOLDERS 20. The CLHIA recommends that provincial governments implement prescribing committees, whose mandate will be to set prescribing standards for prescribers based on a rigorous assessment of the clinical and cost effectiveness of drugs.